jest an update I dropped another 5 lbs since my last post and have only been tacking 1 one pill a day since end of August.
from 225 to 179 , all the naysayers must be in the 33% non-responder group -- our maybe they never actually tried the drug and are talking out of there -- well you know where there heads are and the sun don't shine.
the scientific data is building and as it gains traction the train will depart a bit late in my view, but I'm glad i showed up early and have my seat on this (drug discovery machine).
2.51 times book with 33% Q over Q script growth over the last year. now that's cheep value.
thanks Tiger and Sharon
looks like we average 33.75% Q over Q for the last 4 quarters and the momentum seems strong through the summer witch is vary encouraging.
I held ONIX for over 8 years through all the (new drug) and German BF bs with there partners. i see know reason to think i sell ARNA any time soon even if the pipeline has a setback. new chemical entities take time gain market share and at 33%Q/Q we are well on the way.
back to IV
best of luck, i know from my own experience that rapid weight loss can aggravate the gallbladder, seems counter intuitive to me, but i ended up having it out. dont know about your condition put catabolizing is more work on the hepatic system than metabolizing.
actually it is 225 down to 185 used B x2 day for 6 months got down to 190 stopped for 2 months lost 5 more pounds in that time then started gaining and went back on a month ago and have dropped back to 185. after insurance it cost me about $50 a month.
you can say what you like, this is my personal experience the drug works well for me and over 60% of the peaple that use it.
so keep up your baseless infantile comments, and i hope your life improves.
they cant explain there opinion because it has no basses in fact. B is the proof of concept for a hole new drug discovery system. as to stock performance arna has not worked as well as there first product has for me but time will prove this out. its not really about multiple approvals for a single product but multiple approvals for multiple products.
I believe this is the biggest cross border regulatory "tell" i have seen in the last 30 years.
German regulators or tough and this greatly increases the probability of early DMCB stop on efficacy leading to early approval by the FDA.
no one has any control over when the DSC completes the efficacy part of the review, safety is good and we will see what we get when DSC is finished. the only point you might think about is : GERMANY
This looks like a tell to some or a red flag to AF's followers that are long GERN & VVUS
"The Paul Ehrlich Institute (( PEI )) which is the German equivalent of the FDA has just approved a hospital exemption early access program (similar to compassionate use) for DCVax-L to treat all glioma patients. This Hospital Exemption approval was issued under section 4 ( B ) of the German Medicines Law in which PEI has the authority to provide an exemption from the requirement that a product must complete clinical trials establishing safety and efficacy and then gain regulatory approval before the product can be made available to patients."
the German equivalent of or FDA has given DVCax-L a preliminary pass. Our DSMB will do there jobs, the outcome will be based on the results jest like the German PEI. PEI is a "look" at what is to come and anyone that is tacking the other side had better have more to go on than "A" blogger with a degree in (political science) and an exemplary history as a contra-indicator.
UPDATE as of 3/3/14 I have lost 30#. that's less then the first 2 months per Md's advice to slow the weight lows down. no side effects, sleeping well,
I dont know where people are getting there numbers, maybe im looking at the wrong company but it looks like they have 22m shares. how can 4 % be 27.8 what am i missing?
TAIPEI, Taiwan, Jan 17, 2014. TaiGen Biotechnology Company, Limited ("TaiGen") announced that its parent company, TaiGen Biopharmaceuticals Holdings Ltd., began trading today in the Taiwan GreTai Securities Market under the ticker 4157.TWO. The offering price is NT$ 50 and the company raised NT$ 1.1 billion through the sale of 22 million shares with its initial public offering. The proceeds will be used in advancing TaiGen’s discovery and development pipeline. KGI Securities and SinoPac Securities acts as book-running managers for the offering. TaiGen is valued at NT$ 36.9 billion based on its closing price of NT$53 on January 17th with 696 million shares outstanding.